SAN DIEGO, June 27, 2011 — AltheaDx, Inc. today announced the launch of next-generation sequencing “NGS” services into its clinical molecular pathology lab for application in biomarker discovery and clinical trial testing. AltheaDx intends to utilize NGS for both monitoring known and discovering new complex genetic changes that underlie different cancer types.
+
Headlines
ALL NEWS
AltheaDx Incorporates Next-Generation Sequencing Into Its Clinical Testing Pipeline.
Speak with us at BIO2011, Washington, DC, June 27-30, 2011
Personalized Oncology: The Emergence of Personalized Medicine Strategies in Oncology Clinical Development and Deal Making. Speakers include Dr. Joe Monforte, Ph.D., EVP, CSO, AltheaDx, chaired by John Freshley, CBO Compendia Bioscience
AltheaDx and Compendia Bioscience Launch the Breast Cancer Segregation Panel™
SAN DIEGO — December 8, 2010 — AltheaDx, Inc. today announced the formation of a strategic partnership with Compendia Bioscience to combine their respective core capabilities in assay development, validation and bioinformatics. The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials. From 2006, AltheaDx has enabled FFPE tissue-based biomarker discovery and companion diagnostic development. AltheaDx has facilitated the clinical utilization of biomarkers through validation and clinical sample testing under GLP and/or CLIA.
+
AltheaDx adds Dr. Ann Kessler to the Board of Directors
San Diego, CA, April 28, 2010 – AltheaDx, Inc., a privately held molecular diagnostic company and a leader in the development of companion diagnostics for biopharmaceutical partners, today announced the appointment of Dr. Ann Kessler to the AltheaDx Board of Directors.
+
